2009
DOI: 10.1016/s1470-2045(09)70003-8
|View full text |Cite
|
Sign up to set email alerts
|

Abstract: Summary Background Drug treatments for patients with high-risk myelodysplastic syndromes provide no survival advantage. In this trial, we aimed to assess the effect of azacitidine on overall survival compared with the three commonest conventional care regimens. Methods In a phase III, international, multicentre, controlled, parallel-group, open-label trial, patients with higher-risk myelodysplastic syndromes were randomly assigned one-to-one to receive azacitidine (75 mg/m² per day for 7 days every 28 days)… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
4
1

Citation Types

74
1,948
11
51

Year Published

2011
2011
2022
2022

Publication Types

Select...
6
1

Relationship

0
7

Authors

Journals

citations
Cited by 2,341 publications
(2,084 citation statements)
references
References 34 publications
74
1,948
11
51
Order By: Relevance
“…Since approval for treatment for MDS in 2004,31 parenteral azacitidine has been shown to induce remissions and HI in a range of settings, from first‐line treatment of higher‐risk MDS, CMML and AML to maintenance therapy after alloHSCT 5, 6, 7, 12, 19, 20, 32, 33, 34. CC‐486, is an oral drug formulation of azacitidine.…”
Section: Discussionmentioning
confidence: 99%
See 2 more Smart Citations
“…Since approval for treatment for MDS in 2004,31 parenteral azacitidine has been shown to induce remissions and HI in a range of settings, from first‐line treatment of higher‐risk MDS, CMML and AML to maintenance therapy after alloHSCT 5, 6, 7, 12, 19, 20, 32, 33, 34. CC‐486, is an oral drug formulation of azacitidine.…”
Section: Discussionmentioning
confidence: 99%
“…Parenteral azacitidine has been extensively evaluated in patients with MDS, chronic myelomonocytic leukemia (CMML), and AML in large randomized clinical trials,5, 6, 7 in regional registry studies,8, 9, 10, 11, 12, 13 and in numerous smaller retrospective analyses of patients treated in community practice 14, 15. These studies show azacitidine reduces cytopenias in select lower‐risk MDS and prolongs overall survival (OS) in higher‐risk MDS and AML,5, 6, 7, 16 may be effective maintenance therapy after induction chemotherapy (IC) or allogeneic hematopoietic stem cell transplant (alloHSCT),17, 18, 19, 20 and can induce responses in patients with relapsed/refractory disease 12, 21.…”
Section: Introductionmentioning
confidence: 99%
See 1 more Smart Citation
“…Although azacitidine improves the survival rate in MDS and AML patients (Fenaux et al. 2009, 2010), approximately 40% of the MDS patients fail to respond (Silverman et al. 2002; Fenaux et al.…”
Section: Introductionmentioning
confidence: 99%
“…2002; Fenaux et al. 2009). Prognosis after azacitidine failure is poor both in MDS patients (Prébet et al.…”
Section: Introductionmentioning
confidence: 99%